Research Analysts Issue Forecasts for AGIO Q1 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Monday, February 24th. HC Wainwright analyst E. Bodnar expects that the biopharmaceutical company will post earnings of ($1.53) per share for the quarter. HC Wainwright has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q2 2025 earnings at ($1.61) EPS, Q3 2025 earnings at ($1.40) EPS, FY2025 earnings at ($6.40) EPS, FY2026 earnings at ($7.35) EPS, FY2027 earnings at ($8.37) EPS, FY2028 earnings at ($7.33) EPS and FY2029 earnings at ($5.53) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Several other research firms have also commented on AGIO. Royal Bank of Canada boosted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Finally, Scotiabank upped their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $35.19 on Wednesday. Agios Pharmaceuticals has a one year low of $27.14 and a one year high of $62.58. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 3.10 and a beta of 0.88. The firm has a 50-day simple moving average of $34.01 and a two-hundred day simple moving average of $42.92.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Venturi Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at $33,000. GF Fund Management CO. LTD. purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter worth $39,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals during the fourth quarter valued at $53,000. Sterling Capital Management LLC boosted its holdings in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.